Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, REGENERON PHARMACEUTICALS, INC. reported revenue of $14.34B, up 1.0% year over year. Operating margin was 24.9% and net margin 31.4%, on a free-cash-flow margin of 28.4% with capital expenditure at 6.3% of revenue. Every figure is computed directly from REGN's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $14.34B | 24.9% | 31.4% |
| FY2024 | $14.20B | 28.1% | 31.1% |
| FY2023 | $13.12B | 30.9% | 30.1% |
| FY2022 | $12.17B | 38.9% | 35.6% |
| FY2021 | $16.07B | 55.7% | 50.2% |
How does REGN compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.